(Circulation. 1999;100:475-482.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Elevated Serum Triglyceride Levels and Long-Term Mortality in Patients With Coronary Heart Disease
The Bezafibrate Infarction Prevention (BIP) Registry
From the Department of Internal Medicine "B", Meir General Hospital, Kfar-Saba, Israel (M.H.); Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel (M.H., M.B., S.B., H.R.-R., U.G.); Institute for Physiological Hygiene, Wolfson Medical Center, Holen, Israel (D.B., E.G.); and Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (U.G.).
Correspondence to Uri Goldbourt, PhD, BIP Coordinating Center, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer 52621, Israel.
Background—The association between elevated blood triglyceride levels and subsequent mortality risk in patients with established coronary heart disease (CHD) has been investigated rarely. The aim of the present study was to investigate this association.
Methods and Results—We evaluated mortality over a mean follow-up time of 5.1 years among 9033 male and 2499 female CHD patients who were screened for participation in the Bezafibrate Infarction Prevention (BIP) Study. A stepwise increase in mortality with increasing serum triglyceride levels was observed in patients with desirable or elevated serum total cholesterol levels and in patients with either desirable or abnormally low HDL cholesterol levels. Multivariate adjustment for factors other than HDL cholesterol yielded a slightly increased adjusted mortality risk with a 1-natural-log-unit elevation of triglyceride levels in men (hazard ratio [HR] 1.14, 95% CI 1.00 to 1.30) and women (HR 1.37, 95% CI 1.04 to 1.88). Excess covariate-adjusted risk was noted among patients with elevated total and LDL cholesterol and in women with HDL cholesterol levels >45 mg/dL. After additional adjustment for HDL cholesterol, the risk of mortality with a 1-natural-log-unit elevation of triglycerides declined in men (HR 1.09, 95% CI 0.94 to 1.26) and in women (HR 1.10, 95% CI 0.80 to 1.50). A trend for increased mortality risk remained in patients with elevated total and LDL cholesterol and in women with HDL cholesterol >45 mg/dL.
Conclusions—Elevated triglyceride levels were associated with a small, independent increased mortality risk in CHD patients. This risk may be increased among subgroups of patients with elevated total cholesterol and LDL cholesterol levels.
Key Words: coronary disease • lipoproteins • mortality
This article has been cited by other articles:
 |
|
 |
|
  W.-J. Zhang, K. E. Bird, T. S. McMillen, R. C. LeBoeuf, T. M. Hagen, and B. Frei Dietary {alpha}-Lipoic Acid Supplementation Inhibits Atherosclerotic Lesion Development in Apolipoprotein E Deficient and Apolipoprotein E/Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 22, 2008; 117(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hegele and R. L. Pollex Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1224 - 1227. [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Pejic and D. T. Lee Hypertriglyceridemia. J Am Board Fam Med, May 1, 2006; 19(3): 310 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Genoux, H. Dehondt, A. Helleboid-Chapman, C. Duhem, D. W. Hum, G. Martin, L. A. Pennacchio, B. Staels, J. Fruchart-Najib, and J.-C. Fruchart Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR{alpha} Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nowak, A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M.-R. Taskinen, J. Fruchart-Najib, et al. Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor Mol. Cell. Biol., February 15, 2005; 25(4): 1537 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jakel, M. Nowak, E. Moitrot, H. Dehondt, D. W. Hum, L. A. Pennacchio, J. Fruchart-Najib, and J.-C. Fruchart The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c J. Biol. Chem., October 29, 2004; 279(44): 45462 - 45469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Asia Pacific Cohort Studies Collaboration Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region Circulation, October 26, 2004; 110(17): 2678 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W T. Cade, L. Peralta, and R. E Keyser Aerobic Exercise Dysfunction in Human Immunodeficiency Virus: A Potential Link to Physical Disability Physical Therapy, July 1, 2004; 84(7): 655 - 664. [Full Text] [PDF]
|
|
|
|
|
|
T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haim, V. Boyko, U. Goldbourt, A. Battler, and S. Behar Predictive Value of Elevated White Blood Cell Count in Patients With Preexisting Coronary Heart Disease: The Bezafibrate Infarction Prevention Study Arch Intern Med, February 23, 2004; 164(4): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Austin, K. L. Edwards, S. A. Monks, K. M. Koprowicz, J. D. Brunzell, A. G. Motulsky, M. C. Mahaney, and J. E. Hixson Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia J. Lipid Res., November 1, 2003; 44(11): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vu-Dac, P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al. Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor alpha Activators J. Biol. Chem., May 9, 2003; 278(20): 17982 - 17985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delgado-Rodriguez, M. Medina-Cuadros, A. Gomez-Ortega, G. Martinez-Gallego, M. Mariscal-Ortiz, M. A. Martinez-Gonzalez, and M. Sillero-Arenas Cholesterol and Serum Albumin Levels as Predictors of Cross Infection, Death, and Length of Hospital Stay Arch Surg, July 1, 2002; 137(7): 805 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 The Diabetes Atorvastatin Lipid Intervention DALI The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia Diabetes Care, August 1, 2001; 24(8): 1335 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minnich, N. Tian, L. Byan, and G. Bilder A potent PPAR{alpha} agonist stimulates mitochondrial fatty acid {beta}-oxidation in liver and skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E270 - E279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miida, K. Sakai, K. Ozaki, Y. Nakamura, T. Yamaguchi, T. Tsuda, T. Kashiwa, T. Murakami, K. Inano, and M. Okada Bezafibrate Increases Pre{beta}1-HDL at the Expense of HDL2b in Hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2428 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Austin, B. McKnight, K. L. Edwards, C. M. Bradley, M. J. McNeely, B. M. Psaty, J. D. Brunzell, and A. G. Motulsky Cardiovascular Disease Mortality in Familial Forms of Hypertriglyceridemia: A 20-Year Prospective Study Circulation, June 20, 2000; 101(24): 2777 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]
|
|